Guide for Commenting on ICER’s Draft Evidence Report on Treatments for Amyotrophic Lateral Sclerosis (ALS)
On June 14, 2022, ICER released its draft evidence report, “AMX0035 and Oral Edaravone for Amyotrophic Lateral Sclerosis.” This document provides a framework for considering which aspects of two potential treatments for Amyotrophic Lateral Sclerosis (ALS) are...Read more
